
Shares of Quantum BioPharma Ltd (NASDAQ:QNTM) are on watch Monday morning following a series of updates regarding its lead drug candidate for multiple sclerosis, Lucid-MS. Here’s what investors need to know.
What To Know: The primary catalyst is Monday’s announcement of an agreement with a leading contract development and manufacturing organization to produce an oral formulation of Lucid-MS for its upcoming Phase 2 clinical trial. This move marks a critical step toward testing the drug’s efficacy in humans.